Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 6/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.56 |
| ▸ | PCK1 | P35558 | 2/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5030813 | 0.88 | PCK1 (0.55) | ADORA2BADORA2APCK1ADORA1 | |
| SCHEMBL5035028 | 0.86 | ADORA2B (0.56) | ADORA2BADORA2APCK1ADORA1 | |
| SCHEMBL5033065 | 0.85 | ADORA2B (0.58) | ADORA2BADORA2APCK1ADORA1 | |
| SCHEMBL5033070 | 0.85 | ADORA2B (0.58) | ADORA2BADORA2APCK1ADORA1 | |
| SCHEMBL4413115 | 0.85 | PCK1 (0.61) | ADORA2BADORA2APCK1ADORA1 | |
| SCHEMBL4419729 | 0.82 | ADORA2B (0.64) | ADORA2BADORA2APCK1ADORA1 | |
| SCHEMBL4416377 | 0.82 | ADORA2B (0.62) | ADORA2BADORA2APCK1ADORA1 | |
| SCHEMBL5028605 | 0.81 | ADORA2B (0.58) | ADORA2BADORA2APCK1ADORA1 | |
| SCHEMBL5028610 | 0.81 | ADORA2B (0.60) | ADORA2BADORA2APCK1ADORA1 | |
| SCHEMBL5033078 | 0.80 | PCK1 (0.56) | ADORA2BADORA2APCK1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293705-A1 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ENDACEA, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-7423041-B2 | e.g. 3-[2-(4-Aminophenyl)ethyl]-8-benzyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility | ENDACEA, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-20070161629-A1 | A1 Adenosine Receptor Antagonists | ENDACEA, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-7202252-B2 | A1 adenosine receptor antagonists | ENDACEA, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050119258-A1 | A1 adenosine receptor antagonists | ENDACEA, INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119258-A1 | A1 adenosine receptor antagonists | ADORA1, ADORA2A, ADORA3 | ADORA2B 4/4885ADORA2A 2/4885PCK1 3496/4885 |
| US-20070161629-A1 | A1 Adenosine Receptor Antagonists | ADORA1, ADORA2A, ADORA3 | ADORA2B 4/4885ADORA2A 2/4885PCK1 3496/4885 |
| US-20080293705-A1 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | ADORA2B 4/4885ADORA2A 2/4885PCK1 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.